Summary: Cannabis sales decreased by 0.5% sequentially in May, following a 3.6% decrease in April, according to BDSA’s monthly cannabis sales data. The total sales across the 11 markets amounted to an estimated $1.71 billion during the month. Year-over-year growth in May ranged from -9.5% in Maryland to +31.9% in Michigan in the eastern markets, and from -14.3% in California to -2.0% in Nevada in the western markets.
Keep Yourself Informed
Analyzing the Downward Trend in May Cannabis Sales
According to an exclusive summary of BDSA’s monthly cannabis sales data for 11 states provided by New Cannabis Ventures, cannabis sales decreased by 0.5% sequentially in May, following a 3.6% decrease in April. On a per-day basis, sales decreased by 3.7% sequentially. The total sales across the 11 markets amounted to an estimated $1.71 billion during the month.
In the eastern markets, BDSA provides coverage for Florida, Illinois, Maryland, Massachusetts, Michigan, and Pennsylvania. In May, year-over-year growth ranged from -9.5% in Maryland to +31.9% in Michigan. It’s important to note that Florida, Maryland, and Pennsylvania are medical-only markets, though Maryland introduced adult-use in July. Sequential growth was negative in three markets and in all markets on a per-day basis.
In the western markets, BDSA covers Arizona, California, Colorado, Nevada, and Oregon. In May, year-over-year growth ranged from -14.3% in California to -2.0% in Nevada compared to a year ago. Nevada was the only state of the 11 BDSA tracks that grew on a per-day basis sequentially.
For readers interested in a deeper look at cannabis markets across these eleven states and more, BDSA Solutions can provide access to actionable data and analysis, including segmentation by additional product categories, brand and item detail, longer history, and segmentation by product attributes.[Source: New Cannabis Ventures]
Subscribe to our newsletter
We hope you enjoyed this news update. Check back with us daily to see what’s going on in the world of cannabis and psychedelics. And make sure to subscribe to our Newsletter for all the latest in the industry!
Simply place your email below:
AI Disclaimer: This news update was created using AI tools. PsychePen is an AI author who is constantly improving. We appreciate your kindness and understanding as PsychePen continues to learn and develop. Please note that the provided information is derived from various sources and should not be considered as legal, financial, or medical advice.